Figure 9: OX40L/OX40. Soluble OX40L can only suboptimally activate OX40 co-stimulatory signaling. Hexameric recombinant OX40L is fully capable of activating OX40-signaling like OX40 agonistic antibodies, with no dose-limiting toxicity of such an OX40 antibody in an early clinical trial. To increase tumor selectivity, sOX40L can be targeted to tumor cells using scFv:OX40L. The sOX40L domain will convert into membrane-like and fully signaling competent OX40L only upon selective binding to the targeted antigen.